All stock lists
Generate Biomedicines, Inc. (NASDAQ:GENB)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
14.16+0.31 (+2.24%)
Market cap
$1.82B
Insider Score
Health Score
Analyst consensus
Listed since
Feb 27, 2026
Website
Insider Score
––Not scored
GENB Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
GENB analyst forecast
GENB analyst consensus
Moderate Buy1 ratings
Buy 1 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
GENB 12-month price target
No published price targets in the last 12 months.
GENB ratings mix, last 12 months
Buy Hold Sell
Best analysts covering GENB
No firm covering GENB has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
GENB analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-10-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-28 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-05-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-08 |
GENB earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-08-06 | -0.51 | -0.52 | $5.3M | $6.3M |
| 2026-11-05 | -0.56 | 0.00 | $7.8M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.